July 16, 2009 (FinancialWire) (Investrend Broadcast Syndicate) — Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) (current market cap: US$982.6 mil.) will webcast their company’s Q2 ‘09 earnings conference call today, July 16, 2009, at 5:00 p.m. EDT. The webcast is being carried by VCall, and is directly accessible via the VCall website (http://www.investorcalendar.com/IC/ClientPage.asp?ID=146838).

According to VCall, “Cubist Pharmaceuticals, Inc. is focused on becoming a global leader in the research, development and commercialization of novel pharmaceuticals to combat serious and life-threatening infections. Cubist has filed a New Drug Application with the U.S. Food & Drug Administration for Cidecin® (daptomycin for injection), the first in a new class of investigational antibiotics, and has broadened its pipeline to include multiple pre-clinical drug candidates, including an oral version of ceftriaxone (OCTX), a broad-spectrum cephalosporin antibiotic, and CAB-175, a next generation cephalosporin antibiotic with demonstrated in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA). The company is engaged in a strategic partnership with Novartis Pharma AG for the discovery and development of novel antiinfectives. Cubist is headquartered in Lexington, MA and has operations in Vancouver, BC, Canada and Slough, UK.”

Conference calls are often impacted by market trends, geopolitical conditions, news coming from conferences and economic releases. FinancialWire(tm) provides complete, daily conference call schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “Daily FirstAlert(tm)” (http://www.financialwire.net/news-alerts/), as well as free annual reports on those and thousands of other companies via the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php).  Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.